Preliminary Agenda
Chair: Michal Lotem, Israel & Caroline Robert, France
Michal Lotem
Head of the Hadassah Cancer Research Institute (HCRI), Hadassah Hebrew University Medical Center, Israel
Caroline Robert
Head, Dermatology, Director of the Adaptive Resistance Team
Gustave Roussy and Paris Saclay University, Paris, France
HNRNPH2-Related Neurodevelopmental Disorder: From Molecular Mechanisms to RNA-Based Therapeutics
Rotem Karni
Principal Investigator, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
Turning Junk into Gems: Long Non-Coding RNAs Unlock New Therapeutic Horizons
Alessandro Bonetti
Director, Early Respiratory, AstraZeneca, Cambridge, UK
RNA Signatures of Neurodegeneration: From Human Disease Models to Therapeutic Target Discovery
Matthew White
Senior Research Fellow, Principal Investigator, King’s College London, UK
Chairs: Michal Lotem, Israel & Caroline Robert, France
From Atoms to Sequences: Integrated Physics and AI for RNA Therapeutics
Jacopo Manigrasso
Director, Nucleic Acids Department, Nostrum Biodiscovery, Barcelona, Spain
RCS-21: Development of a First-in-Class Macrophage-Targeted Inhalation RNA Therapeutic
Stefan Engelhardt
Director, Institute of Pharmacology and Toxicology, Technical University of Munich (TUM), Germany
Structural Nanomedicine: Programming Innate Immunity Across Diseases
Natalie Artzi
Associate Institute Director and Core Faculty, Wyss Institute at Harvard University, Cambridge, MA, USA
Antibody-Oligo-Conjugate (AOC) Platform for the Treatment of Peripheral Neuropathies
Oren Bogin
CTO, Potentia Bio, Tel Aviv, Israel
When Mis-Translation Meets Immunotherapy
Reuven Agami
Head, Division of Oncogenomics, Netherlands Cancer Institute, Amsterdam, The Netherlands
Horizon Europe for Health: Opportunities, Calls, and Strategy 2027
Anna Abelmann-Brockmann
Head of WKS, Scientific Coordinator, Bavarian Research Alliance (BayFor), Munich, Germany
Chair: Ernesto Guccione, USA
The Effect of Multi Omics on Clinical Decision Making
Aron Popovtzer
Director of the Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, Israel
Discovery of a New Class of RNA-Binding Proteins
Matthias W. Hentze
Director, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
Chair: Rotem Karni, USA
Industry Presentation
TBD
Wuxi AppTec
Industry Presentation
NHP demonstration of bispecific siRNA platform and lead drug to reduce cardiometabolic risk
Michael Khan
CEO, Argonaute RNA, Bristol, UK
Chair: Matthias W. Hentze, Germany
MATR3-Driven 3′-to-5′ Structural Relay Promotes OXPHOS mRNAs Translation during Myogenesis
Imed Gallouzi
Professor, Bioscience Chair, Center of Excellence for Smart Health Biomedical Sciences, King Abdullah University of Science and Technology, Thuwal,
Saudi Arabia
Rethinking Mechanisms of mRNA Vaccine Immunity
Brian D. Brown
Director, Icahn Genomics Institute; Vice Chair, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Translation of Circular RNAs: From Regulation to Application
Zefeng Wang
Chair, Professor, School of Life Science, Southern University of Science and Technology, Shenzhen, China
The Roles of Protein-RNA Feedback in Cellular Homeostasis
Jernej Ule
Centre Director and Professor of Neurodegeneration Research, Francis Crick Institute and King’s College London, UK
Chair: Rotem Karni, USA
From ASO Design to Delivery: The TechNOA Platform Applied to Urea Cycle Disorders (UCD)
Ernesto Guccione
Principal Investigator, The Guccione Lab, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Crossing the BBB: Delivering RNA Therapeutics to the CNS for the Treatment of Neuromuscular and Neurological Disorders
Saul Martinez Montero
Executive Director, RNA Therapeutics, Dyne Therapeutics, Boston, MA, USA
Manipulating Leukocytes Function with RNAs via Targeted Lipid Nanoparticles: From Concept to the Clinic
Dan Peer
Director of the Laboratory of Precision NanoMedicine and Vice President for Research, Tel Aviv University (TAU), Israel
Chair: Aron Popovtzer, Israel
Genome Regulation by Non-Coding Transcription
Piero Carninci
Head of Genomics Research Centre, Functional Genomics, Human Technopole, Milan, Italy
A Critical View of Anti-Cancer Cell Therapies and the Alternatives Offered
by mRNA
Michal Lotem
Head of the Hadassah Cancer Research Institute (HCRI), Hadassah Hebrew University Medical Center, Israel
Mapping, Functional Characterization and Therapeutic Targeting of RNA Structural Ensembles in Living Cells
Danny Incarnato
Associate Professor of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, The Netherlands
Moderator:
Noga Yerushalmi, Investment Director, M Ventures, Yavne, Israel
Panelists:
Nadiya Ishnazarova, Principal, Venture Investments, Johnson & Johnson Innovation JJDC Inc, Amsterdam, The Netherlands
Anthony D. Saleh, CEO, miRecule Inc., Bethesda, MD, USA
Philipp Schreppel
Senior Director Business Development, Ethris, Planegg, Germany
Sponsored by Oxford University Press
SNORD81 Regulates Translation via the Multisynthetase Complex
Carsten Müller-Tidow
Director of Internal Medicine, Hematology, Oncology, Rheumatology, Heidelberg University Hospital, Germany
From Jumping Genes to RNA Therapeutics: Retrotransposons in the Tumor Microenvironment
Beatrice Bodega
Principal Investigator, Professor of Molecular Biology, Co-Founder and Consultant, T-One Therapeutics, INGM and University of Milan, Italy
RIBOncology: Harnessing Cancer Genomics for (Non-Coding) RNA Biology and Therapeutics
Rory Johnson
Associate Professor, Laboratory for Genomics of Long Noncoding RNA and Disease, University College Dublin, Ireland
Precision RNA Strategies to Disrupt Fusion Oncogenes
Kathy Liu
Principal Investigator, Associate Professor, Department of Biochemistry & Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Targeting RNA Translation to Enhance Immune Surveillance of Drug-Tolerant Melanoma Persister Cells
Caroline Robert
Head, Dermatology, Director of the Adaptive Resistance Team, Gustave Roussy and Paris Saclay University, Paris, France
Chair: Claudio Sette, Italy
A Novel Splice Site Polymorphism-Guided Adoptive Immunotherapy for Hematologic Malignancies
Andrei Thomas-Tikhonenko
Director of Experimental Pathology, Children’s Hospital of Philadelphia, PA, USA
GC Content as a Major Determinant of RNA Splicing
Xavier Roca
Associate Professor, School of Biological Sciences, Nanyang Technological University Singapore, Singapore
U2 snRNP Inhibition Hampers Cancer Cell Viability by Disrupting DNA Repair Proficiency and Mitotic Checkpoint Integrity
Claudio Sette
Principal Investigator, Catholic University of the Sacred Heart, School of Medicine, Rome, Italy
Direct Activation of cGAS Drives Interferon-Independent Antitumor Immunity
Matteo Iannacone
Director of the Division of Immunology, Transplantation and Infectious Diseases, Professor of Pathology, and Head of the Dynamics of Immune Responses laboratory
San Raffaele Scientific Institute and University, Milan, Italy
RNA Quality Control through m6A Modification
Julian König
Chair of Biochemistry and RNA-Biology, Theodor-Boveri-Institute,
Julius Maximilian University of Würzburg, Germany
Stop the Nonsense: MYC Induces NMD Dependency in Lymphoma
Bruno Amati
Group Leader, Department of Experimental Oncology, European Institute of Oncology (IEO), Milan, Italy
Biological Activity and Regulation of the Nonsense-Mediated Decay (NMD) Pathway
Javier F. Caceres
MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, UK
